Macmillan: Review of drug information

Macmillan: Review of drug information

BOPA Members – Help required!

Macmillan produces many cancer drug treatment pages. They are widely used by healthcare professionals and people affected by cancer across the UK. We work hard to ensure that they provide the information people need to understand their treatment and ask questions. These online pages also link to other sources of information and support about cancer types, types of treatments, and managing side effects. The information needs to be current, clinically accurate and reflect the real-world patient experience.  We rely on expert speciality pharmacists to review our drug information, and make suggestions, to ensure we have met our goal.

We are always looking for specialist oncology and haematology pharmacists to join our review panel. We ask that our reviewers complete a short survey so that we can capture contact details, specialities and interests in a way that is GDPR compliant. We have a protected database to keep these details secure.

The help can range from looking at a couple of pages once or twice a year, or more if you are able. We are always flexible, you can always say “I am not able to this time” or “yes I can review, if you can give me more time”. We always appreciate that people are kindly giving us their time and expertise and we are very grateful.

We send the pages as Word documents. We ask if you could add comments and/or mark any changes using the ‘Track changes’ facility. Or you may prefer to email us with your comments.
We are generally looking for:

  • Is the information clinically accurate and up-to-date?
  • Are there any issues that you feel we have left out?
  • Is there anything that you think could have been explained more clearly?
  • Feel free to add any other comments that you have.

If you would like to join our professional reviewers or would like to find out more please contact Helen Purdon at [email protected]

Thank you for your ongoing help,
Best wishes,
Helen

Helen Purdon (She/her)
Cancer Information Development Nurse

The below pages are to be reviewed soon:

  • Stilboestrol
  • Palbociclib
  • Ribociclib
  • Doxorubicin
  • Doxorubicin and ifosfamide
  • Gefitinib
  • Midostaurin
  • De Gramont/modified de Gramont
  • Cisplatin and 5FU
  • Leuprorelin
  • CODOX-M
  • Torifemine
  • GemCarbo
  • Crizotinib
  • Rasburicase
  • EPO
  • G-CSF
  • Cabazitaxel
  • TC
  • CVP
  • Bendamustine
  • Encorafenib and binimetinib
  • Mesna

Latest News

By NHS Infusions and Special Medicines Programme on 4th September 2026

Expressions of interest for Expert Panel Sub Group to support the approval and implementation of Standardised Product Specifications

Expressions of interest for Expert Panel Sub Group to support the approval and implementation of Standardised Product Specifications The Infusions and Special Medicines Programme is inviting expressions of interest for…

Read article
By BOPA on 31st August 2026

🌟 BOPA Advanced Pharmacist Study Day – Elevate Your Practice, Shape Your Career

Are you an oncology or haematology pharmacist with around five or more years of experience — whether Band 7 or Band 8 — and ready to take the next step…

Read article
By BOPA Executive Committee on 31st August 2026

BOPA 2026 Executive Committee Election – One week left to cast your vote

One week left to cast your vote for the BOPA Executive Committee Election. Have your say at BOPA’s future.   In 2026 we received 9 nominations for 6 positions. -Standard…

Read article
By BOPA Executive Committee on 27th August 2026

UK multidisciplinary Consensus Document – Safe Management of Hazardous Medicinal Products in UK Healthcare Settings

We are pleased to jointly publish the new UK multidisciplinary consensus document, Safe Management of Hazardous Medicinal Products in UK Healthcare Settings. Hazardous medicinal products (HMPs) are used across a…

Read article